Pediatric PET/MR Image Registry

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03458520

Enrollment

100

Registered

2018-03-08

Start date

2018-02-01

Completion date

2026-12-31

Last updated

2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma, Osteosarcoma, Soft Tissue

Brief summary

The purpose of this study is to compare whole body magnetic resonance (MR) imaging, whole body positron emission tomography (PET)/MR imaging, and (if available) PET/Computed Tomography (CT) imaging for the diagnosis of tumors in children and young adults. Sensitivities, specificities and diagnostic accuracies of the different imaging modalities will be compared for significant differences.

Interventions

DIAGNOSTIC_TESTPET/MR imaging

undergo PET/MR imaging

DIAGNOSTIC_TESTMR imaging

Undergo MR imaging

DIAGNOSTIC_TESTPET/CT imaging

Undergo PET/CT imaging

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 40 Years

Healthy volunteers

Inclusion criteria

* Patients with proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumor. * We might also include some patients with leukemia if there is concern for a focal lesion in any of their organs. * Participant's parents (if participant is under 18) or the participant (if participant is 18 years or older) must willingly give written informed consent prior to any image transfer to the image registry.

Exclusion criteria

* Patient has contraindications for MRI or PET/MR. This includes patients with cardiac pacemakers or intracranial vascular clips as well as patients with a blood glucose level \> 200 mg/dl. * Lack of parental permission (if participant is younger than 18) or lack of informed consent (if participant is at least 18 years of age). * Patient has a CNS primary tumor. * Pregnant women and fetuses

Design outcomes

Primary

Measure	Time frame	Description
Number of tumors	up to 12 months	Number of tumors detected on whole body MRI, PET/MR and (if available) PET/CT scans.

Secondary

Measure	Time frame	Description
Metabolic activity of tumors	up to 12 months	Metabolic activity of tumors determined by Standardized Uptake Values (SUV) on PET/MR and (if available) PET/CT scans.

Countries

United States

Contacts

CONTACTAnne Muehe

amuehe@stanford.edu650-720-8601

PRINCIPAL_INVESTIGATORHeike Daldrup-Link, MD

Stanford University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026